Spruce Biosciences Inc. (SPRB): Price and Financial Metrics


Spruce Biosciences Inc. (SPRB): $1.42

0.06 (+4.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SPRB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SPRB Stock Price Chart Interactive Chart >

Price chart for SPRB

SPRB Price/Volume Stats

Current price $1.42 52-week high $15.08
Prev. close $1.36 52-week low $1.25
Day low $1.31 Volume 38,500
Day high $1.44 Avg. volume 305,215
50-day MA $1.80 Dividend yield N/A
200-day MA $3.63 Market Cap 33.36M

Spruce Biosciences Inc. (SPRB) Company Bio


Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.


SPRB Latest News Stream


Event/Time News Detail
Loading, please wait...

SPRB Latest Social Stream


Loading social stream, please wait...

View Full SPRB Social Stream

Latest SPRB News From Around the Web

Below are the latest news stories about Spruce Biosciences Inc that investors may wish to consider to help them evaluate SPRB as an investment opportunity.

Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN FRANCISCO, February 03, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., MPH, Chief Executive Officer, and Samir Gharib, President and Chief Financial Officer, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022 at 5

Yahoo | February 3, 2022

Spruce Biosciences falls 9% amid pipeline update, outlook

Spruce Biosciences (SPRB) provided an update on its clinical programs and financials.The company said it accelerating patient recruitment in the CAHmelia studies, which

Seeking Alpha | January 24, 2022

Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022

SAN FRANCISCO, January 24, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, upcoming milestones and strategic priorities for enhancing the design of and accelerating patient recruitment into the CAHmelia studies, which are evaluating tildacerfont for the treatment of adult classic congen

Yahoo | January 24, 2022

Marquette Asset Management, LLC Buys Vanguard Total Bond Market ETF, ARK Next Generation ...

Investment company Marquette Asset Management, LLC (Current Portfolio) buys Vanguard Total Bond Market ETF, ARK Next Generation Internet ETF, TAT Technologies, Avantis International Equity ETF, Dril-Quip Inc, sells Vanguard Short-Term Corporate Bond ETF, Vanguard Total Stock Market ETF, Vanguard FTSE Developed Markets ETF, Concord Acquisition Corp, Astrotech Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Marquette Asset Management, LLC.

Yahoo | January 20, 2022

Spruce Biosciences (SPRB) Gets a Buy Rating from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Spruce Biosciences (SPRB – Research Report), with a price target of $20.00. The company's shares closed last Wednesday at $3.56, close to its 52-week low of $2.25. According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -22.1% and a 20.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spruce Biosciences with a $9.50 average price target.

Catie Powers on TipRanks | January 6, 2022

Read More 'SPRB' Stories Here

SPRB Price Returns

1-mo -19.32%
3-mo -37.44%
6-mo -44.96%
1-year -89.95%
3-year N/A
5-year N/A
YTD -68.16%
2021 -81.65%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.529 seconds.